PROJECT SUMMARY This proposal responds to the NOSI funding opportunity announcement for women’s complementary/alternative health approaches in IDeA states to more effectively manage women’s health. Immune-mediated diseases typically show a female preponderance and looking at all autoimmune diseases combined, 8 of 10 patients are females. Although not as prominent, gender differences in inflammatory bowel disease (IBD) have been reported for epidemiology, disease presentation, disease course and complications, medical and surgical therapies, adherence, psychosocial functioning, and psychiatric co-disorders (Greuter et al., 2020). IBD (including Crohn’s disease (CD) and ulcerative colitis (UC)) has significant and progressive health issues affecting women. The Department of Gastroenterology and Internal Medicine subdivision of LSU Health Sciences Center in Shreveport serves a predominantly minority-based urban population with a large rural catchment area. Our IBD patients historically received their infusions of biologic therapy (Remicade, Cimizia) as a ‘nurse only visit’ at our infusion center. However, starting March 2019, we started having one of the GI fellows and faculty see all IBD patients during these infusion visits. These brief visits included an interview with the patient about his/her current symptoms, review of their labs and drug levels and assessed if there was need to complete any care gaps (endoscopy, abdominal imaging, vaccinations, etc.). These ‘STABILITY’ (symptomatic review during biologic therapy) visits took ~15 minutes. Based on our first preliminary study of symptomatic review during biologic infusion therapy (STABILITY) in IBD patients in this service area for the period of March 2019 to March 2020 this approach improves disease control at earlier phases and maintains patient clinical progress at reduced cost and with fewer hospitalizations. Surveyed patients expressed unanimous enthusiasm for continued STABILITY review with their doctors during infusion visits Hypothesis. Based on these preliminary findings, it is our hypothesis that very modest changes in disease review in female patients with IBD can dramatically improve their outcomes and reduce hospitalizations. Aim 1. Determine in which female patients (African-American vs. white, age group, socioeconomic status, insurance status, etc.) does ‘STABILITY’ review improve patient outcomes, their quality of life while at the same time reducing overall costs of care. Aim 2. Which clinical features of IBD (such as disease severity, CRP, calprotectin, sedimentation rate and other inflammatory biomarkers) are best improved by ‘STABILITY’ review. Aim 3. Incorporate the results of our study into the clinical decision support system providing individualized symptom management recommendations to clinicians at the point of care to improve outcomes of female IBD patients.